Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer to Evaluate the Safety, Tolerability and Preliminary Efficacy

Next Previous
Trial Profile

A Study of LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer to Evaluate the Safety, Tolerability and Preliminary Efficacy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LK-101 (Primary) ; Durvalumab; Pembrolizumab
  • Indications Carcinoma; Non-small cell lung cancer; Small cell lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 08 Dec 2025 Planned number of patients changed from 40 to 60.
  • 08 Dec 2025 Planned End Date changed from 30 Dec 2026 to 30 May 2028.
  • 08 Dec 2025 Planned primary completion date changed from 30 Jul 2025 to 30 May 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top